{
    "id": 1843,
    "fullName": "MAP2K4 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type MAP2K4 indicates that no mutation has been detected within the MAP2K4 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6416,
        "geneSymbol": "MAP2K4",
        "terms": [
            "MAP2K4",
            "JNKK",
            "JNKK1",
            "MAPKK4",
            "MEK4",
            "MKK4",
            "PRKMK4",
            "SAPKK-1",
            "SAPKK1",
            "SEK1",
            "SERK1",
            "SKK1"
        ]
    },
    "variant": "wild-type",
    "createDate": "09/22/2014",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19521,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer xenograft models with wild-type MAP2K4 and MAP3K1 did not respond to treatment with Selumetinib (AZD6244) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34182,
                "profileName": "MAP2K4 wild-type MAP3K1 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19522,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer cells with wild-type MAP3K1 and wild-type MAP2K4 were sensitive to the combination therapy of Selumetinib (AZD6244) and Vizimpro (dacomitinib), demonstrating decreased cell proliferation in culture and reduced tumor volume in cell line xenograft models (PMID: 29795445).",
            "molecularProfile": {
                "id": 34182,
                "profileName": "MAP2K4 wild-type MAP3K1 wild-type"
            },
            "therapy": {
                "id": 9056,
                "therapyName": "Dacomitinib + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19520,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung cancer xenograft models with wild-type MAP2K4 and MAP3K1 did not respond to treatment with Selumetinib (AZD6244) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34182,
                "profileName": "MAP2K4 wild-type MAP3K1 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19519,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, breast cancer xenograft models with wild-type MAP2K4 and MAP3K1 did not respond to treatment with Selumetinib (AZD6244) (PMID: 29795445).",
            "molecularProfile": {
                "id": 34182,
                "profileName": "MAP2K4 wild-type MAP3K1 wild-type"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17004,
                    "pubMedId": 29795445,
                    "title": "MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29795445"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1814,
            "profileName": "MAP2K4 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34182,
            "profileName": "MAP2K4 wild-type MAP3K1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}